Place of drug therapy in the prevention and treatment of bone complications of prostate cancer
Bone complications of prostate cancer are serious problem faced by both patients and clinicians. Prevention of bone complications remains one of the major challenges for oncourologists. With the advent of new drugs, treatment options are gradually extending; furthermore, effectiveness of the treatment also increases. The use of bisphosphonates, particularly zoledronic acid, is the treatment of choice for the prevention of bone complications in patients with prostate cancer. However, the high efficacy of denosumab in prevention of bone complications and its effect on the tumor process gives the way for thinking about the preferability of treatment.